These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 2733696)

  • 1. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
    Chang RS; Lotti VJ; Chen TB; Kunkel KA
    Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
    Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
    Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand.
    Chen TB; Lotti VJ; Chang RS
    Mol Pharmacol; 1992 Dec; 42(6):1077-82. PubMed ID: 1480133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
    Zhou W; Povoski SP; Bell RH
    J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
    Knapp RJ; Vaughn LK; Fang SN; Bogert CL; Yamamura MS; Hruby VJ; Yamamura HI
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1278-86. PubMed ID: 2262906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
    Chang RS; Lotti VJ
    Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.
    Chang RS; Lotti VJ; Chen TB
    Biochem Pharmacol; 1987 May; 36(10):1709-14. PubMed ID: 3593394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization.
    Zhou W; Povoski SP; Longnecker DS; Bell RH
    Cancer Res; 1992 Dec; 52(24):6905-11. PubMed ID: 1458479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
    Lotti VJ; Chang RS
    Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
    Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrin/CCK-B receptors on brain, gastric parietal cells and ECL carcinoid tumor of Mastomys natalensis.
    Nakata H; Matsui T; Ito M; Chiba T
    Kobe J Med Sci; 1993 Dec; 39(5-6):161-70. PubMed ID: 8182917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives.
    Makovec F; Peris W; Frigerio S; Giovanetti R; Letari O; Mennuni L; Revel L
    J Med Chem; 1996 Jan; 39(1):135-42. PubMed ID: 8568800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.